Announcements Trials
Browse Landscape

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Observational 2

Sponsor

Conditions

Hereditary Cancer 2

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Diagnostic Tests, Routine × Clear all
NCT03067389 2019-01-15

Combined Breast Cancer Risk Study

Myriad Genetic Laboratories, Inc.

Completed
553 enrolled

Hereditary Cancer

NCT03081455 2017-08-08

Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes

Myriad Genetic Laboratories, Inc.

Completed
145 enrolled

Hereditary Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡